Broadly, neutralizing antiviral antibodies holds great promise for improving treatment opportunities for patients suffering from viral infections (e.g., human immunodeficiency virus [HIV], hepatitis B virus [HBV], cytomegalovirus [CMV], Rabies, Ebola, Zika) leading to serious health disorders or even to death without effective antiviral treatment. The potential of antibodies in host protection against lethal viral infections has been demonstrated in numerous animal models and is best exemplified by the protection conferred to neonates by maternal antibodies. Over the past few decades, virus-neutralizing human monoclonal antibodies (nAbs) have been isolated from humans successfully cured of disease using a wide range of recently developed antibody isolation technologies. In this chapter, we present an approach for isolating recombinant human nAbs from combinatorial gene libraries being cloned from individuals who have recovered from viral infections. The presented protocols describe the selection and screening of antiviral single-chain antibody fragments (scFvs) from phage display immune libraries. This technology represents a well-established, high-throughput approach allowing fast selection of broadly neutralizing, antiviral antibodies. The protocols for generating and selecting antigen-specific scFvs can be applied for the selection of scFvs against any target.
Introduction
Antibodies are powerful tools for the prophylaxis and treatment of viral infections. The use of antibodies against severe, life-threatening infections began in the 1890s when Robert Koch demonstrated that administration of sheep antiserum against diphtheria toxin to a girl dying from diphtheria infection led to her rapid recovery and survival [1] . On that basis, numerous attempts to treat potentially deadly viral diseases such as influenza, severe acute respiratory syndrome (SARS), or Ebola by administrating sera from survivors have successfully been undertaken [2] . Further improvements led to the development of polyclonal hyperimmunoglobulin G (IgG) preparations, consisting of purified antibodies from seropositive donors [3] . Several hyperimmunoglobulins against human cytomegalovirus (CMV), hepatitis B virus (HBV), rabies, and other viral infections are available on the market. Although polyclonal preparations provide strong antiviral activity, the major disadvantage of such hyperimmunoglobulin preparations is that they include a high amount of nonspecific antibodies and only a low proportion of neutralizing antibodies. The development of hybridoma technology by Köhler & Milstein in 1975 revolutionized science and medicine and led to the isolation of numerous monoclonal antibodies [4] . Since the commercialization of the first therapeutic monoclonal antibody product in 1986, this class of therapeutics has grown significantly [5] . In 2016, 5 of the top 20 pharmaceuticals were therapeutic antibody drugs [6] . The vast majority of monoclonal antibodies is approved for the treatment of cancers, multiple sclerosis, or rheumatoid arthritis [7] . However, numerous potent human or humanized antiviral antibodies against H5N1 influenza virus, human immunodeficiency virus (HIV), herpes simplex virus (HSV), human cytomegalovirus (CMV), hepatitis C virus (HCV), Ebola virus, severe acute respiratory syndrome (SARS) virus, and other viral infections are in preclinical development, clinical studies, or even approved for antiviral treatment [2, [7] [8] [9] [10] [11] [12] . Antibodies mostly neutralize free viruses by targeting the initial stages of virus infection described as the binding of free virions to permissive target cells followed by entry and replication [2] . Neutralizing antibodies not only provide new tools for prophylaxis and therapy of viral diseases, but also identify conserved epitopes that may be used to design new vaccines capable of conferring broader protection [11] . However, enveloped viruses such as HIV-1, HSV-1/2, CMV, and measles can also move between adjacent cells without diffusing through the extracellular environment (cell-to-cell spread). This mechanism facilitates rapid viral dissemination, promotes immune evasion from the host's immune response, and enhances the progression of disease [13] . We recently described a murine monoclonal antibody (mAb) capable of inhibiting the cell-to-cell spread of HSV. This antibody proved to be highly effective in the prevention of drug-resistant HSV infections in highly immunodeficient NOD/SCID mice indicating the enormous potential of antibody blocking mechanisms crucial for the virus spread [12] . Due to these unique features, this antibody was humanized for clinical applications and is now being tested in phase I and II trials. Besides the generation of antiviral antibodies by humanization approaches, neutralizing antibodies can also be isolated from humans cured of viral infections, such as SARS or Ebola [9, 14] . Various methods have been developed for the isolation of antibodies from humans including B-cell immortalization and single-cell expression cloning [15] . Among these approaches, high-throughput screening of phage-displayed antibody libraries has become one of the leading technologies for generating human therapeutic antibodies (Figure 1 ) [16] . Nowadays, very large phage display libraries from naive (IgM) B-cell repertoires (>10 10 independent clones) are widely used for the selection of human antibodies against a broad panel of targets including human self-antigens to identify high-affinity binders. However, these antibodies are not affinity-matured by the human immune system. Hence, the preparation of combinatorial immune libraries from immunized or infection cured donors can deliver a broader range of highly functional antibodies, even from smaller libraries (i.e., potent antiviral antibodies with broadly neutralizing efficacies). For instance, the selection of combinatorial immune repertoires (>10 8 independent clones) from HSV seropositive donors resulted in a broad panel of various high-affinity binders with partly HSV-neutralizing properties [17, 18] .
Although various other in vitro selection platforms have been developed during the last decades (e.g., ribosome display and yeast display), phage display using filamentous phages is predominantly used for library generation since it is robust, inexpensive, and allows the automation of the selection and screening process. Due to the limitation in the production of fulllength IgG antibodies in Escherichia coli, only smaller antibody fragments (e.g., scFvs or Fabs) can be efficiently expressed within the E. coli periplasm as functional proteins. Several systems Figure 1 . Isolation of human neutralizing antiviral antibodies (nAbs) by phage display technique. Lymphocytes comprising B-cells from humans harboring neutralizing antibodies with unique features, e.g., Ebola disease survivors are isolated from blood, spleen, lymph nodes, or bone marrow by standard techniques (e.g., PBMCs by Ficoll density gradient centrifugation). Lymphocytes RNA is prepared and transcribed into single-stranded cDNA that is used as the source for PCR amplification of the variable heavy (VH) and light chain (VL) genes. Variable genes are randomly cloned into phagemid vectors as scFv antibody fragments prior to electroporation of phagemids into E. coli bacteria to produce combinatorial immune libraries. Library glycerol stocks are then used for the generation of a bacterial culture that is superinfected with a helper phage to produce phages presenting different scFvs on their surface. Specific binding scFvphages are enriched over several selection rounds by stringent washing and elution using antigen/virions immobilized on immunotubes. After screening for monoclonal binders on ELISA plates, the best specific binders are directly produced as monovalent scFvs in bacteria cultures or cloned into appropriate expression vectors for the production of Fab, or various bivalent antibody formats prior to functional analysis (e.g., virus neutralization capacity and affinity).
for displaying antibody fragments on the phage surface have been developed over time using different vectors and phage coat proteins for display. The most common type (3 + 3 system) is based on phagemid vectors where the antibody gene fragments are cloned as fusions with the pIII phage gene. Cloning of the antibody gene repertoires can be done by using different strategies in one, two, or three independent steps where the variable light and heavy chain genes are PCR-amplified and randomly combined into reliable phagemid vectors. In the-one step cloning strategy, the VH and VL genes are separately amplified with an overlapping, additional linker sequence and combined by assembly PCR [19] . In the two-step cloning strategy, mostly the VL gene repertoire is cloned first into the phagemid followed by insertion of Figure 2 . Workflow of the selection and screening procedure. For the selection of antigen-specific scFv-phages, logphase library cultures are packed by superinfection with helper phages (for the preparation of helper phages, see Protocol I) that provide all proteins necessary for phage propagation (see Protocol A). After IPTG induction, expressed scFv-pIII fusions are inserted within the produced phages leading to the presentation of scFv antibody fragments on the phage surface. After determination of phage titer (see Protocol B), specific binding scFv-phages are enriched over several selection rounds by stringent washing and elution on recombinant antigen/virions that have been immobilized onto immunotubes (see Protocol C). Successful enrichment of specific binding scFv-phages can be analyzed by polyclonal phage ELISA (ppELISA) (see Protocol D) prior to screening of monoclonal antibodies as scFv-phages by monoclonal phage ELISA (mpELISA) (see Protocol E-I) or as soluble scFvs (see Protocol E-II). After the identification of bacterial colonies encoding for full-length scFvs by colony PCR and sequencing (see Protocol F), soluble scFvs can be produced in the periplasm of bacteria (see Protocol G) or variable antibody genes can be cloned into mammalian expression vectors to produce Fab or various bivalent antibody fragments. Finally, antibody fragments can be analyzed for their neutralizing activity in functional assays like the plaque reduction neutralization test (PRNT) (see Protocol H).
the VH repertoire into the VL phagemid [17, 18, [20] [21] [22] . In the three-step cloning strategy, two separate VH and VL libraries are prepared before exercising one repertoire and including it into the phagemid containing the other repertoire [23] . After electroporation of the phagemids into electrocompetent E. coli bacteria, the antibody libraries are grown on selection plates and stored as frozen bacterial glycerol stocks. Prior to PCR amplification of the variable antibody genes, B-cells from respective donors need to be isolated. In the case of viral infection and depending on when the infection occurred, the isolation of the short-lived plasmablast pool during the early antibody response or the long-lived memory B-cell and plasma cell pool may be preferred. Although the isolation of peripheral blood mononuclear cells (PBMC) from whole blood (the main source for plasmablasts) is often described for retrieving antiviral antibodies, B-cell sources such as spleen, lymph nodes (many memory B-cells), or bone marrow (the main source of plasma cells) might be considered for library construction. Good protocols for the cloning of combinatorial scFv phage display libraries including the primer sets for PCR amplification of antibody genes can be found elsewhere [17, [20] [21] [22] and are out of the scope of this chapter.
Here, we present a methodology for the recovering of potential therapeutic antibodies with unique antiviral properties from human B-cell repertoires (for workflow see Figure 2 ). This strategy has been successfully used for generating neutralizing human antibodies against HSV as a proof-of-principle [18] . The following protocol will systematically describe the procedure of generating broadly neutralizing antiviral antibodies from isolated human B-cells by a phage display technique.
Preliminary notes
Before starting antibody phage display, please be aware that phages are highly stable and decontamination of workspace and consumables is hard to achieve. It is best to do phage work in a special lab keeping equipment/material separated from the common bacterial workspace, especially when antibody library construction is performed. If not possible, phage work should be carried out in at least a separate workspace including a separate hood, shaker, and centrifuge. Inactivation of phage solutions can be done by incubation with diluted bleach (caution, always wear personal protection during handling) and/or sterilizing workspaces with UV light. For decontamination of tubes and Erlenmeyer flasks, bleach can be added to water-filled tubes and incubated overnight before washing, rinsing, and autoclaving. In common, single-use material is preferred for phage work. Collect phage-contaminated solutions in glass flasks and inactivate by adding bleach before dumping. Only use polypropylene (PP) tubes since phages might stick to other kinds of plastics. To prevent contamination to pipettes, always use barrier tips.
Presented protocols are intended for the selection and screening of antibody libraries based on the scFv antibody format being cloned in phagemid vectors as pIII fusion with an intrinsic amber stop codon and under the lac promoter (inducible by IPTG, repressible by glucose). Many current antibody phage display libraries are constructed in phagemid vectors with listed features (e.g., most derivatives of pHEN, pComb3X, pHAL, and pCANTAB), although other selection relevant features such as signal peptides, molecular tags, etc., might differ. Please check features of your antibody library used prior to selection and screening and change protocols accordingly if necessary. If using libraries based on phagemid vectors with lac promoter, always add ≥2% glucose to the media to repress scFv-pIII protein expression as long as antibody phages are not produced. Lower amounts of glucose results in background expression of pIII fusions and clones with growth advantages (e.g., truncated scFvs) might overgrow leading to a reduced library diversity. More detailed information about antibody phage display [24] and commonly used phagemid vectors can be found elsewhere [25] .
Independent of the source of your antibody library, always try to package antibody libraries from primary bacteria stocks, never from secondary stocks or using phage-packaged libraries to infect bacteria. Only correctly stored (−80°C) primary glycerol bacteria stocks guarantee highest initial antibody diversity. For novel libraries or if not familiar with antibody phage display, perform test selection and subsequent screening using not relevant proteins such as bovine serum albumin.
Materials

A. Preparation of scFv-phages
• 2xTY medium: 16 g/l tryptone, 10 g/l yeast extract, 5 g/l NaCl, dissolved in ultrapure water, autoclaved, and stored at room temperature (RT).
• 2xYT-GA: 900 ml 2xYT medium, supplemented with 100 ml glucose stock solution and 1 ml ampicillin stock solution right before use.
• Kanamycin stock solution (2000×): 100 mg/ml kanamycin sulfate dissolved in ultrapure water, filter-sterilized, stored at −20°C.
• Ampicillin stock solution (1000×): 100 mg/ml ampicillin sodium salt dissolved in ultrapure water, filter-sterilized, stored at −20°C.
• 20% (w/v) glucose stock solution (10×): 200 g/l d-glucose dissolved in ultrapure water, filter-sterilized, stored at 4°C.
• Helper phage VCSM13 (Agilent Technologies) or M13K07 (e.g., NEB Biolabs), Kanamycinresistant.
• Optional for oligomeric display: hyperphage M13 K07ΔpIII (Progen Biotechnik).
• 2xYT-GK agar plates (100 mm): 16 g tryptone, 10 g yeast extract, 5 g NaCl, and 15 g agar dissolved in 900 ml ultrapure water, autoclaved, cooled down to 50°C, and supplemented with 100 ml glucose stock solution and 500 μl kanamycin stock solution right before pouring, stored at 4°C.
• 1 M IPTG stock solution (20,000×): 2.38 g isopropyl β-d-1-thiogalactopyranoside dissolved in 10 ml ultrapure water, filter-sterilized, stored at −20°C.
• Induction medium 2xYT-AKI: 2xYT supplemented with 1 ml ampicillin stock solution, 500 μl kanamycin stock solution, and 50 μl IPTG stock solution (IPTG concentration depending on phagemid vector used), no glucose (!), prepared right before use.
• Polypropylene (PP) centrifugation tubes: 2 and 50 ml (single-use), 250 ml (reusable).
• PEG/NaCl solution: 200 g/l polyethylene glycol 6000, 146.1 g/l NaCl, dissolved in ultrapure water, autoclaved, stored at 4°C.
• Optional for Western blot analysis: primary murine anti-pIII monoclonal IgG (MoBiTec, diluted 1:1000 milk in phosphate-buffered saline (MPBS)) and secondary goat anti-mouse HRP-conjugated antibody (Jackson ImmunoResearch, diluted 1:10,000 in MPBS).
B. Determination of the phage titer
• TG1 bacteria strain (e.g., Lucigen).
• M9 minimal stock solution (5×): 56.4 g/l M9 minimal salt (Sigma Aldrich) dissolved in ultrapure water, autoclaved, stored at 4°C.
• 1 M MgSO 4 stock solution: 6.02 g MgSO 4 dissolved in 50 ml ultrapure water, filter-sterilized, stored at 4°C.
• Thiamine stock solution: 50 mg thiamine hydrochloride dissolved in 50 ml ultrapure water, filter-sterilized, stored at −20°C.
• M9/+Thi minimal plates (100 mm): 15 g agar dissolved in 780 ml ultrapure water, autoclaved and supplemented with 200 ml M9 minimal salt stock solution, 20 ml glucose stock solution (see A), 1 ml MgSO 4 solution, and 1 ml thiamine stock solution.
• 2xYT-GA agar plates (100 mm): 16 g tryptone, 10 g yeast extract, 5 g NaCl, and 15 g agar dissolved in 900 ml ultrapure water, autoclaved, cooled down to 50°C, and supplemented with 100 ml glucose stock solution and 1 ml ampicillin stock solution right before pouring, stored at 4°C.
C. Selection of antigen-specific scFv-phages
• 5 ml Nunc MaxiSorp™ immunotubes (Thermo Fisher Scientific).
• Phosphate-buffered saline (PBS): 1.42 g/l Na 2 HPO 4 , 0.24 g/l KH 2 PO 4 , 0.2 g/l KCl, 8.0 g/l NaCl, dissolved in ultrapure water, adjusted to pH 7.4, autoclaved, stored at RT.
• PBST: phosphate-buffered saline supplemented with 0.1% Tween20.
• MPBS: 2% nonfat dry milk in phosphate-buffered saline, prepared right before use.
• 2xYT-GA agar plates (100 mm round, 150 mm round, or 245 mm square): see B.
• Phage elution buffer: 0.1 M glycine-HCl, 0.5 M NaCl, dissolved in ultrapure water, adjusted to pH 2.2, filter-sterilized, stored at 4°C.
• Phage neutralization buffer: 1 M Tris-HCl dissolved in ultrapure water, adjusted to pH 9.5, filter-sterilized, stored at 4°C.
• Trypsin-PBS solution: 10 μg/ml trypsin (e.g., from porcine pancreas by Sigma Aldrich) dissolved in PBS, pH 7.4, prepared right before use.
D. Polyclonal phage ELISA (ppELISA)
• PBS and PBST: see C.
• 96-well microtiter ELISA plate (e.g., Nunc Maxisorp™ by Thermo Fisher Scientific).
• Murine anti-M13 monoclonal antibody HRP-conjugate (GE Healthcare), diluted 1:5000 in MPBS.
• TMB substrate solution (e.g., Thermo Fisher Scientific).
• Stop solution (2 M H 2 SO 4 ): concentrated sulfuric acid dissolved 1:9 in ultrapure water.
E. Screening for monoclonal binders (I) Monoclonal phage (mpELISA) screening:
• Sterile 96-well polypropylene round-bottom microplates (e.g., Greiner Bio-One).
• Breathable sealing membrane for microplates (e.g., Sigma Aldrich).
• 96-pin microplate replicator (Boekel Scientific).
• 8-channel pipettes (20 μl and 200 μl).
• 2xYT-glycerol: 2xYT dissolved in 50% glycerol and 50% ultrapure water, autoclaved, stored at RT.
• 2xYT-GA medium, ampicillin stock solutions, glucose stock solution, kanamycin stock solution, IPTG stock solution, helper phage VCSM13 or M13K07, and induction medium 2xYT-AKI: see A.
• PBS, PBST: see C.
• Maxisorb™ ELISA plates, anti-M13 monoclonal HRP-conjugate, TMB substrate, and stop solution: see D.
(II) Soluble scFv screening:
• HB2151 bacterial strain (Nordic BioSite).
• M9/+Thi minimal plates, 2xYT-GA plates: see B.
• 2xYT medium, ampicillin stock solution, glucose stock solution: see A.
• Sterile 96-well PP round-bottom microplates, breathable sealing membrane, microplate replicator, 8-channel pipettes: see E-I.
• 1 M sucrose stock solution: 342.3 g/l dissolved in ultrapure water, filter-sterilized, stored at 4°C.
H7.
Add 500 μl/well of the scFv-virus mixtures to each well and tilt plates as described above. Include virus only to every plate. ScFvs should be tested in at least duplicates.
H8.
Incubate plates at 37°C for about 1 h (time can vary between 30 and 90 min depending on the cell/virus). During incubation, carefully tilt all the plates 10-15 min.
H9.
Remove inoculum and wash cells with 3 ml/well PBS.
H10
. Add 3 ml/well CMC medium and incubate plates in the humidified incubator (37°C, 5% CO 2 ) for three days.
H11.
Fixate the cells with formaldehyde solution (3 ml/well for 5 min) and stain with crystal violet solution (800 μl/well) for 2 min.
H12. Wash wells once with PBS and twice with ultrapure water (2 ml/well). When analyzing serial dilutions of scFvs, percentage of neutralization can be plotted against scFvs concentration to determine the PRNT 50 values.
After functional characterization, produced scFvs should be characterized for specificity and affinity in binding to recombinant antigen and, more importantly, to intact virions. The specificity of scFvs to recombinant proteins can be easily analyzed by ELISA using recombinant virus antigens (or virus lysates). While scFv affinities has to be determined by kinetic measurements (e.g., by surface plasmon resonance or biolayer interferometry), estimation of apparent scFv affinities can be quickly performed by ELISA. Therefore, recombinant antigen is coated on ELISA plates and 1:2 serial dilutions of purified scFvs (e.g., 1 μM start concentration) are incubated in triplicates followed by detection via tagspecific IgGs and anti-IgG HRP conjugate. The half-maximal effective concentration (EC 50 ) of saturated binding corresponds to the KD value and can be used for affinity ranking of scFvs. However, immobilization of antigens/virions on plastic can alter conformation of coated proteins leading to antibodies recognizing epitopes that are not found on intact virions. Alternatively, binding affinity of antibody fragments can also be estimated by flow cytometry using antigen overexpressing cell lines [30] , e.g., by using Vero cell being infected with HSV [18, 28] .
In conclusion, broadly neutralizing human monoclonal antibodies represent an excellent opportunity for the prevention and therapy of viral infections and are a potent tool to identify neutralizing epitopes on viral proteins for vaccine approaches. Phage display technology became a potent tool to isolate human neutralizing antibodies and should be considered as a validated technique for future approaches.
I. Production of helper phage
Larger preparation of helper phage (VCSM13 or M13K07) being used for superinfection to prepare scFv-phages for selection (Protocol A) and screening (Protocol E-I) can be obtained following the protocol below. Hyperphage cannot be produced without recombinant E. coli strain and must be purchased.
I1.
Thaw primary phage stock and prepare 10 2 dilutions (100 μl) in 2xYT medium.
I2.
Mix helper phage dilution with equal volume of log-phase TG1 culture prepared as described above (see B1-B3) to infect bacteria at 37°C (30 min standing and 30 min shaking).
I3.
Melt top agar in a microwave, aliquot in glass tubes while hot, and cool down tubes to 42°C in a prewarmed water bath.
I4.
Pipette infected bacteria to top agar tubes, mix quickly, and immediately cast top agar onto prewarmed (37°C) 2xYT plates. Grow plates overnight at 30°C (Note 30).
I5. The next day, pick a single small plaque from grown bacteria lawns and transfer into 3 ml 2xYT that was inoculated with 100 μl of TG1 overnight culture right before.
I6
. Incubate culture for 3 h at 37°C while shaking and use grown culture to inoculate 500 ml of 2xYT.
I7.
After one further hour of growing, add 200 μl kanamycin stock solution and grow overnight at 37°C while shaking.
I8.
The next day, pellet bacteria (4000 × g, 10 min, 4°C), transfer 40 ml of supernatant into 50 ml PP tubes and precipitate phage as described in Protocols A8-A10 (Note 31).
I9.
To inactivate the remaining bacteria, either heat helper phage preparation for 15 min at 65°C (recommended) or filter through low protein binding 0.45 μm filter (Note 32).
I10. Aliquot the phage preparation into 2 ml PP tubes and snap freeze the tubes in liquid nitrogen prior to storage at ≤−20°C.
I11.
Determine phage titer as plaque-forming unit (pfu/ml) as described above (see I1-I4) using 1:10 serial phage dilutions from 10 8 to 10 13 for infecting 100 μl log phage TG1 and counting plaques on countable plates (Note 33).
Notes
Note 1: To minimize loss of diversity, very large libraries (>10 9 independent clones) should always be stored as sublibraries that can be separately packed and combined prior to selection. Antibody selection should be only performed with freshly packaged (sub-)libraries that have been kept at 4°C for short as possible. Due to loss of diversity, we do not recommend selection with frozen phage preparations or phage antibodies that have been packaged from secondary library stocks. Importantly, minimize freeze and thaw steps of your primary library and keep it frozen at −80°C until needed.
Note 2:
Correct growing temperature is crucial for phage display. Too low a temperature (<34°C) might result in ineffective formation of pili that are necessary for successful infection by phage.
Note 3:
Oligomeric display of scFvs in the first round of selection by infection with hyperphage can greatly improve selection efficacy and can reduce loss of interesting binders during the initial selection step improving the average display from 0.01 up to 5 antibody fragments per phage. Please note that hyperphage infection results in scFv-phages without wild-type pIII proteins that are necessary for successful infection. To restore the wild-type infectivity, hyperphage-packed libraries should be eluted by a protease cutting between the antibody fragment and the pIII protein (e.g., trypsin works well for pSEX and most pHEN derivatives). To check for suitable proteases for your phagemid, you might analyze your vector on PeptideCutter (ExPASy database) and perform Western blot analysis of digested antibody phages using an anti-pIII antibody for detection (see Note 8) .
Note 4: Expression of scFv-pIII fusion proteins with lac promoter-based phagemid vectors can be performed by using glucose-free media without or a low concentration of IPTG (about 5 μM to 500 μM final concentration depending on used phagemid). However, strong induction of the lac promotor by too high concentration of IPTG might reduce the expression of complete scFv-pIII fusion proteins. Induction conditions should be optimized and antibody presentation on phages can be analyzed by SDS PAGE and Western blot using primary antipIII detection system (see Note 8) .
at a lower speed (about 180 rpm) can be performed although oxygen supply is reduced as
